Human epidermal growth factor receptor 2 in combined hepatocellular-cholangiocarcinoma: Prognostic and predictive guide for adjuvant chemotherapy

Table 2 Clinicopathological characteristics of patients in the human epidermal growth factor receptor 2 positive group after propensity score matching

Characteristic	Median (IQR) or n (%)		P value
	Chemotherapy group (n = 7)	Non-chemotherapy group (n = 14)
Sex			0.533
Male	7 (100.0)	12 (85.7)
Female	0	2 (14.3)
Age	57 (54-65)	56.5 (53.8-61.5)	0.793
HBV			0.870
Present	4 (57.1)	10 (71.4)
Absent	3 (42.9)	4 (28.6)
Liver cirrhosis			0.640
Present	4 (57.1)	5 (35.7)
Absent	3 (42.9)	9 (64.3)
ALB (g/L)	41.1 (38.1-43.1)	42.4 (39.5-45.8)	0.232
TBIL (μmol/L)	22.9 (13.5-24.8)	17.7 (13.6-21.1)	0.117
PT (sec)	11.2 (10.6-11.9)	11.2 (10.7-12.3)	0.911
AFP (ng/mL)			0.877
> 40	4 (57.1)	6 (42.9)
≤ 40	3 (42.9)	8 (57.1)
Satellite lesions			1.000
Present	1 (14.3)	2 (14.3)
Absent	6 (85.7)	12 (85.7)
Microvascular invasion
Present	0	0
Absent	7 (100.0)	14 (100.0)
Macrovascular invasion			0.844
Present	2 (28.6)	2 (14.3)
Absent	5 (71.4)	12 (85.7)
Lymphatic node metastasis			0.100
Present	2 (28.6)	0
Absent	5 (71.4)	14 (100.0)
Maximum tumor diameter (cm)			1.000
≤ 5	3 (42.9)	7 (50.0)
> 5	4 (57.1)	7 (50.0)
CA19-9 (U/mL)			1.000
≤ 25	3 (42.9)	7 (50.0)
> 25	4 (57.1)	7 (50.0)
Histological grade			1.000
High/median	4 (57.1)	8 (57.1)
Low	3 (42.9)	6 (42.9)
TLS score			0.782
3	2 (28.6)	3 (21.4)
2	2 (28.6)	5 (35.7)
1	2 (28.6)	2 (14.3)
0	1 (14.3)	4 (28.6)

IQR: Interquartile ranges; CA19-9: Carbohydrate antigen 19-9; HBV: Hepatitis B virus; ALB: Albumin; TBIL: Total bilirubin; PT: Prothrombin time; AFP: Alpha-fetoprotein; TLS: Tertiary lymphoid structures.